共 151 条
- [1] Farber HW(2004)Pulmonary arterial hypertension N Engl J Med 351 1655-1665
- [2] Loscalzo J(2000)Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions Pharmacol Rev 52 269-324
- [3] Vaudry D(2001)Vasoactive intestinal peptide: cardiovascular effects Cardiovasc Res 49 27-37
- [4] Gonzalez BJ(2003)Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension J Clin Invest 111 1339-1346
- [5] Basille M(2008)Differential roles of endothelin-1 ETA and ETB receptors and vasoactive intestinal polypeptide in regulation of the airways and the pulmonary vasculature in isolated rat lung Exp Physiol 93 1210-1219
- [6] Yon L(1988)Vasoactive intestinal peptide prevents increase in pulmonary artery pressure during hypoxia in newborn lambs Ann N Y Acad Sci 527 686-687
- [7] Fournier A(1984)VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF) Peptides 5 325-328
- [8] Vaudry H(1992)Differential effects of PACAP and VIP on the pulmonary and hindquarters vascular beds of the cat J Appl Physiol 72 1212-1217
- [9] Henning RJ(2007)Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene Circulation 115 1260-1268
- [10] Sawmiller DR(2004)Pulmonary hypertension and right heart failure in pituitary adenylate cyclase-activating polypeptide type I receptor-deficient mice Circulation 110 3245-3251